Current share price for CTS : $0.575 0.005 (0.88%)+
Ceretas Limited (CTS) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is engaged in research and development of a novel therapeutic ultrasound technology licensed from UniQuest for the purpose of commercialising a portable, image-guided therapeutic ultrasound platform designed for the treatment of neurodegenerative disease, particularly Alzheimer's disease.
| ASX Code | CTS |
| Website | http://www.ceretas.com.au |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | n/a |
| CTS Share Price | $0.575 |
| Day High | $0.575 |
| Day Low | $0.575 |
| Last Close | $0.570 |
| CTS Share Price Movement | $0.01 ( 0.88% ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Ceretas Limited (CTS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$0.18 | -$0.30 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2025 A | 2025 A | ||||||||
| Cochlear Limited (COH) | $7,979M | 0.0171 | -0.1894 | 0.0615 | 20.3867 | 25.1505 | 23.6925 | 3.52% | 2.84% | 2.95% |
| Ceretas Limited (CTS) | $28M | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $20,890M | 0.1388 | 0.1458 | 0.1883 | 53.7880 | 46.9447 | 39.5047 | 1.22% | 1.32% | 1.49% |
| ResMed Inc. (RMD) | $18,646M | 0.3087 | 9.7744 | 0.0595 | 215.8872 | 20.0370 | 18.9119 | 1.07% | 1.12% | 1.18% |
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 0.00 | 0.00 |
| Market | 0.31 | 13.10 | 1.15 | 0.65 |
| Sector | 0.72 | 19.70 | 1.67 | 1.87 |
| Name | Position | Start Date |
|---|---|---|
| Ms Rachel de las Heras | Chief Executive Officer, Managing Director | 11 Mar 2025 |
| Dr Anthony J Keating | Executive Director | 20 Dec 2024 |
| Mr John Keep | Non-Executive Chairman, Non-Executive Director | 22 Nov 2024 |
| Mr Stuart Crozier | Non-Executive Director | 20 Feb 2026 |
| Mr Samuel Alan Wetzler | Non-Executive Director | 21 Oct 2024 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|
See all changes in directors' interest & trades for Ceretas Limited (CTS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Nicola (Nicki) Maxine Farley | Company Secretary |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.